Harrow, Inc.

HROW

US4158581094

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 04:00:00 2024-07-15 pm EDT			5-day change	1st Jan Change
24.85 ^USD	+5.25%		+10.64%	+121.88%

Jul. 09	Harrow Agrees to Supply Products to Apexus Under 340B Prime Vendor Program	MT
Jun. 24	Harrow, Inc.(NasdaqGM:HROW) added to S&P Pharmaceuticals Select Industry Index	CI

Imprimis Pharmaceuticals, Inc. will Change its Name to Harrow Health, Inc

January 02, 2019 at 12:00 am EST

Effective January 02, 2019, Imprimis Pharmaceuticals, Inc. will change its name to Harrow Health, Inc.

Latest news about Harrow, Inc.

Harrow Agrees to Supply Products to Apexus Under 340B Prime Vendor Program	Jul. 09	MT
Harrow, Inc.(NasdaqGM:HROW) added to S&P Pharmaceuticals Select Industry Index	Jun. 23	CI
Craig-Hallum Adjusts Price Target on Harrow Health to $30 From $26, Buy Rating Maintained	Jun. 21	MT
Harrow Provides TRIESENCE Relaunch Update	Jun. 20	CI
Harrow, Inc. Announces 52-Week Data from VEVYE ESSENCE-2 Open-Label Extension Study	Jun. 05	CI
Lake Street Raises Price Target on Harrow to $25 From $20, Maintains Buy Rating	Jun. 03	MT
B. Riley Raises Price Target on Harrow Health to $29 From $26, Keeps Buy Rating	May. 15	MT
Transcript : Harrow, Inc., Q1 2024 Earnings Call, May 14, 2024	May. 14
Harrow Health Q1 Core Net Loss Widens, Revenue Increases -- Shares Rise After-Hours	May. 13	MT
Harrow, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Harrow Names Greg Dipasquale as Senior Vice President, Head of Commercial	May. 13	CI
Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target	Apr. 11	MT
B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating	Mar. 22	MT
Top Midday Decliners	Mar. 20	MT
Harrow, Inc. Provides Earnings Guidance for the Year 2024	Mar. 20	CI
Transcript : Harrow, Inc., Q4 2023 Earnings Call, Mar 20, 2024	Mar. 20
Harrow Health Slumps 13% Premarket After Swinging to Core Net Loss in Q4 While Sales Jumped	Mar. 20	MT
North American Morning Briefing : Markets on Hold as Fed Decision Nears	Mar. 20	DJ
Harrow, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19	CI
Harrow, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Restore stock falls as weak tech trading drags down annual results	Mar. 14	AN
Harrow, Inc. Announces Board of Director Appointments	Jan. 29	CI
Harrow Health's Eye Treatment Drug Vevye Now Available in US	Jan. 11	MT
Harrow Announces Availability of Vevye® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease	Jan. 11	CI
Harrow Collaborating With Three Health Technology Platforms for US Launch of Vevye	Jan. 03	MT

Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

Sector

Pharmaceuticals

Calendar

2024-07-16 - American Society of Retina Specialists Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Harrow, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

23.61 USD

Average target price

29.15 USD

Spread / Average Target

+23.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HARROW, INC.	+121.88%	835M
ELI LILLY AND COMPANY	+63.05%	854B
NOVO NORDISK A/S	+39.42%	636B
JOHNSON & JOHNSON	-4.78%	361B
MERCK & CO., INC.	+17.52%	324B
ABBVIE INC.	+8.43%	301B
ASTRAZENECA PLC	+14.19%	247B
ROCHE HOLDING AG	+5.81%	230B
NOVARTIS AG	+16.77%	228B
AMGEN INC.	+14.63%	177B

Other Pharmaceuticals

Harrow, Inc.

Equities

HROW

US4158581094

Pharmaceuticals

Imprimis Pharmaceuticals, Inc. will Change its Name to Harrow Health, Inc

Latest news about Harrow, Inc.

Chart Harrow, Inc.

Company Profile

Income Statement Evolution

Ratings for Harrow, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals